Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP527188.RAxLLHo_hINRPDLm4ECQV86ZUxZbcS0lhwehQQ_Qt6iK4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP527188.RAxLLHo_hINRPDLm4ECQV86ZUxZbcS0lhwehQQ_Qt6iK4130_assertion type Assertion NP527188.RAxLLHo_hINRPDLm4ECQV86ZUxZbcS0lhwehQQ_Qt6iK4130_head.
- NP527188.RAxLLHo_hINRPDLm4ECQV86ZUxZbcS0lhwehQQ_Qt6iK4130_assertion description "[We therefore analyzed 102 large-cell carcinomas by immunohistochemistry for TTF-1 and ?Np63/p40 as classifiers for adenocarcinoma and squamous cell carcinoma, respectively, and correlated the resulting subtypes with nine therapeutically relevant genetic alterations characteristic of adenocarcinoma (EGFR, KRAS, BRAF, MAP2K1/MEK1, NRAS, ERBB2/HER2 mutations and ALK rearrangements) or more common in squamous cell carcinoma (PIK3CA and AKT1 mutations).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP527188.RAxLLHo_hINRPDLm4ECQV86ZUxZbcS0lhwehQQ_Qt6iK4130_provenance.
- NP527188.RAxLLHo_hINRPDLm4ECQV86ZUxZbcS0lhwehQQ_Qt6iK4130_assertion evidence source_evidence_literature NP527188.RAxLLHo_hINRPDLm4ECQV86ZUxZbcS0lhwehQQ_Qt6iK4130_provenance.
- NP527188.RAxLLHo_hINRPDLm4ECQV86ZUxZbcS0lhwehQQ_Qt6iK4130_assertion SIO_000772 23196793 NP527188.RAxLLHo_hINRPDLm4ECQV86ZUxZbcS0lhwehQQ_Qt6iK4130_provenance.
- NP527188.RAxLLHo_hINRPDLm4ECQV86ZUxZbcS0lhwehQQ_Qt6iK4130_assertion wasDerivedFrom befree-20150227 NP527188.RAxLLHo_hINRPDLm4ECQV86ZUxZbcS0lhwehQQ_Qt6iK4130_provenance.
- NP527188.RAxLLHo_hINRPDLm4ECQV86ZUxZbcS0lhwehQQ_Qt6iK4130_assertion wasGeneratedBy ECO_0000203 NP527188.RAxLLHo_hINRPDLm4ECQV86ZUxZbcS0lhwehQQ_Qt6iK4130_provenance.